Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reported beneficial ownership of 74,711 shares of Ensysce Biosciences common stock, representing 3.15% of the company's outstanding shares based on 2,370,698 shares reported in the companys quarterly report. The position is held through Adage entities for which Adage acts as investment manager, and the filing shows shared voting and shared dispositive power over the reported shares rather than sole control.
The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. Because the disclosed stake is below 5%, the filing classifies the ownership as a non-control disclosure under Schedule 13G/A.
Positive
None.
Negative
None.
Insights
TL;DR: Adage disclosed a modest 3.15% stake (74,711 shares); disclosure signals transparency but is not a control position.
The filing documents a minority position held by Adage Capital Management and two principals with shared voting and dispositive power. The stake is calculated from an outstanding share base of 2,370,698 shares as reported in the companys quarterly report, producing the 3.15% figure. Because this is a Schedule 13G/A and the reporting persons certify the holdings are in the ordinary course and not intended to influence control, the near-term market or governance impact is limited. Investors should treat this as an informative ownership disclosure rather than a strategic shift in control.
TL;DR: Ownership is material enough to note but remains below the 5% reporting threshold for activist intent; classification indicates non-control.
The structure described shows Adage acting as investment manager for Adage Capital Partners, with Messrs. Atchinson and Gross identified as managing members of related entities that collectively hold the shares. The reporting of shared voting and shared dispositive authority is consistent with manager-led holdings. The certification that the position is held in the ordinary course and not for control purposes aligns with Schedule 13G treatment and implies routine investment management rather than activist engagement.
FAQ
What stake did Adage report in Ensysce Biosciences (ENSC)?
The filing reports beneficial ownership of 74,711 shares, representing 3.15% of Ensysce's outstanding common stock (based on 2,370,698 shares outstanding as reported).
Who filed the Schedule 13G/A for ENSC?
The statement was filed by Adage Capital Management, L.P. and two individuals, Robert Atchinson and Phillip Gross, in their capacities related to Adage entities.
Does the filing indicate Adage seeks to influence control of Ensysce (ENSC)?
No. The filing includes a certification that the securities were acquired and are held in the ordinary course of business and are not held for the purpose of changing or influencing control of the issuer.
What voting and disposition rights are reported?
The filing reports 0 shares with sole voting/dispositive power and 74,711 shares with shared voting and shared dispositive power for each reporting person.
Is the reported position considered a 5% or greater stake under SEC thresholds?
No. The reported 3.15% ownership is below the 5% threshold referenced in Item 5 and therefore is characterized as ownership of 5 percent or less of the class.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Ensysce Biosciences, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
293602504
(CUSIP Number)
06/30/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
293602504
1
Names of Reporting Persons
Adage Capital Management, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
74,711.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
74,711.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
74,711.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.15 %
12
Type of Reporting Person (See Instructions)
IA, PN
SCHEDULE 13G
CUSIP No.
293602504
1
Names of Reporting Persons
Robert Atchinson
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
74,711.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
74,711.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
74,711.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.15 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
CUSIP No.
293602504
1
Names of Reporting Persons
Phillip Gross
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
74,711.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
74,711.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
74,711.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
3.15 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Ensysce Biosciences, Inc.
(b)
Address of issuer's principal executive offices:
7946 Ivanhoe Avenue, Suite 201, La Jolla, CA 92037
Item 2.
(a)
Name of person filing:
This statement is filed by:
(i) Adage Capital Management, L.P., a Delaware limited partnership ("ACM"), as the investment manager of Adage Capital Partners, L.P., a Delaware limited partnership ("ACP"), with respect to the shares of common stock, par value $0.0001 per share ("Common Stock") of Ensysce Biosciences, Inc., a Delaware corporation (the "Company") directly held by ACP;
(ii) Robert Atchinson ("Mr. Atchinson"), as (1) managing member of Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware ("ACA"), managing member of Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware ("ACPGP"), general partner of ACP and (2) managing member of Adage Capital Partners LLC, a Delaware limited liability company ("ACPLLC"), general partner of ACM, with respect to the shares of Common Stock directly held by ACP; and
(iii) Phillip Gross ("Mr. Gross"), as (1) managing member of ACA, managing member of ACPGP and (2) managing member of ACPLLC, general partner of ACM, with respect to the shares of Common Stock directly held by ACP.
The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.
The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.
(b)
Address or principal business office or, if none, residence:
The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.
(c)
Citizenship:
ACM is a limited partnership organized under the laws of the State of Delaware. Messrs. Gross and Atchinson are citizens of the United States.
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP No.:
293602504
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
The percentage set forth in this Schedule 13G is calculated based upon an aggregate of
2,370,698 shares of Common Stock outstanding as of May 8, 2025, as reported in the
Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31,
2025, filed with the Securities and Exchange Commission on May 13, 2025.
(b)
Percent of class:
3.15%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a).
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Adage Capital Management, L.P.
Signature:
/s/ Robert Atchinson
Name/Title:
By: Adage Capital Partners LLC, its General Partner, By: Robert Atchinson, its Managing Member
